Erman Akkus: Is patient participation in cancer drug trials associated with longer survival compared with routine care?

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“Is patient participation in cancer drug trials associated with longer survival compared with routine care? .

• No survival benefit
• When only high-quality studies were pooled (HR, 0.9)
• When the sample was adjusted for possible publication bias (HR, 0.94)
• Interpretation of authors: Excluding patients from trials due to geography, nonavailability of trials in their condition, or ineligibility does not deprive them of survival opportunities
• doi:10.1001/jama.2024.6281″

Source: Erman Akkus/X